Metagenomi Reports Q1 2026 Financials: Collaboration Revenue Plummets 70%, Key Partnership Modified
MGX is trading near its 52-week low of $1.25 (9.2% above the low).
Summary
Metagenomi Therapeutics reported a sharp decline in Q1 collaboration revenue and a significant modification to its Ionis partnership, signaling headwinds despite a stable cash runway.
Key Events · Earnings and Guidance · MGX
-
Collaboration Revenue Plummets
Collaboration revenue decreased by 70% year-over-year to $1.2 million in Q1 2026, down from $4.1 million in Q1 2025.
-
Ionis Collaboration Modified
The drug discovery plan for one Wave 1 target was modified, leading to additional costs and extended timing. The exploratory research plan was discontinued, with a potential one-time non-cash revenue reversal expected in Q2 2026.
-
Cash Runway Confirmed
The company expects its existing cash, cash equivalents, and marketable securities of $140.2 million as of March 31, 2026, to fund operations for at least the next 12 months from the filing date.
-
Ongoing Securities Litigation
A class action lawsuit alleging misleading statements regarding the Moderna collaboration continues, with the court having partially denied the defendants' motion to dismiss on March 24, 2026.
Analysis · MGX · Life Sciences
Metagenomi Therapeutics' Q1 2026 results reveal a significant 70% year-over-year decline in collaboration revenue, a critical metric for this pre-revenue biotech. The modification of the Ionis collaboration, including the discontinuation of exploratory research and a potential revenue reversal, raises concerns about future pipeline development and revenue streams. While the company maintains a 12-month cash runway, the substantial revenue drop and ongoing securities litigation present considerable challenges.
At the time of this filing, MGX was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.8M. The 52-week trading range was $1.25 to $3.95. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.